AMGEN INC (NASDAQ: AMGN)

AMGEN INC

NASDAQ: AMGN (Amgen Inc.)

Last update: 03 Apr, 1:24PM

309.82

4.12 (1.35%)

Add to watchlist

Previous Close	305.70
Open	310.40
Volume	1,492,761
Avg. Volume (3M)	3,132,393
Market Cap	166,436,847,616

Price / Earnings (TTM)	41.04
Price / Earnings (Forward)	14.77
Price / Sales	4.95
Price / Book	27.94

52 Weeks Range	253.30 (-18%) — 346.85 (11%)
Earnings Date	1 May 2025
TTM Dividend Yield	2.95%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Mixed	Bullish
	Drug Manufacturers - General (Global)	Mixed	Bullish
Stock	Amgen Inc.	Bullish	Bullish

AIStockmoo Score

-0.6

Analyst Consensus	-1.5
Insider Activity	NA
Price Volatility	2.0
Technical Moving Averages	-2.5
Technical Oscillators	-0.5
Average	-0.63

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
AMGN	166 B	2.95%	41.04	27.94
GILD	127 B	3.03%	268.87	7.22
AZN	230 B	2.26%	30.43	6.19
SNY	149 B	6.88%	25.00	1.48
GRFS	6 B	-	26.84	0.710
BIIB	21 B	-	12.64	1.20

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.22%
% Held by Institutions	82.02%

52 Weeks Range	253.30 (-18%) — 346.85 (11%)
Price Target Range	294.00 (-5%) — 330.00 (6%)
High	330.00 (Morgan Stanley, 6.51%)	Hold
Median	324.00 (4.58%)
Low	294.00 (B of A Securities, -5.11%)	Sell
Average	314.40 (1.48%)
Total	2 Buy, 2 Hold, 1 Sell
Avg. Price @ Call	295.19

Firm	Date	Target Price	Call	Price @ Call
Morgan Stanley	09 Apr 2025	330.00 (6.51%)	Hold	308.88
B of A Securities	05 Mar 2025	294.00 (-5.11%)	Sell	316.57
B of A Securities	06 Feb 2025	275.00 (-11.24%)	Sell	297.78
Piper Sandler	10 Feb 2025	329.00 (6.19%)	Buy	294.79
Citigroup	28 Jan 2025	295.00 (-4.78%)	Hold	280.30
RBC Capital	24 Jan 2025	324.00 (4.58%)	Buy	275.42

No data within this time range.

Date	Type	Details
11 Apr 2025	Announcement	IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
09 Apr 2025	CNBC	Pharmaceutical stocks rise as Trump pauses tariffs but not for China
03 Apr 2025	Announcement	UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
08 Mar 2025	Announcement	AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
05 Mar 2025	CNBC	Amgen starts two critical late-stage trials for weight loss drug MariTide
04 Mar 2025	Announcement	AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
01 Mar 2025	Announcement	POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
28 Feb 2025	Announcement	AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
20 Feb 2025	CNBC	From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
14 Feb 2025	Announcement	AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
07 Feb 2025	Announcement	AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
04 Feb 2025	Announcement	AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
31 Jan 2025	Announcement	AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
17 Jan 2025	Announcement	FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
17 Jan 2025	CNBC	Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
Show more

TTM Dividend Yield	2.95%
5Y Average Dividend Yield	3.06%
Payout Ratio	119.05%
Expected Next Dividend Payment	Sep 2025

Ex Date	Announcement Date	Payment Date	Details
16 May 2025	04 Mar 2025	06 Jun 2025	2.38 Cash
14 Feb 2025	10 Dec 2024	07 Mar 2025	2.38 Cash
18 Nov 2024	25 Oct 2024	09 Dec 2024	2.25 Cash
16 Aug 2024	02 Aug 2024	06 Sep 2024	2.25 Cash
16 May 2024	06 Mar 2024	07 Jun 2024	2.25 Cash
15 Feb 2024	12 Dec 2023	07 Mar 2024	2.25 Cash
16 Nov 2023	24 Oct 2023	08 Dec 2023	2.13 Cash
17 Aug 2023	01 Aug 2023	08 Sep 2023	2.13 Cash
17 May 2023	07 Mar 2023	08 Jun 2023	2.13 Cash
14 Feb 2023	12 Dec 2022	08 Mar 2023	2.13 Cash
16 Nov 2022	28 Oct 2022	08 Dec 2022	1.94 Cash
17 Aug 2022	03 Aug 2022	08 Sep 2022	1.94 Cash
16 May 2022	02 Mar 2022	08 Jun 2022	1.94 Cash
14 Feb 2022	03 Dec 2021	08 Mar 2022	1.94 Cash
15 Nov 2021	21 Oct 2021	08 Dec 2021	1.76 Cash
16 Aug 2021	30 Jul 2021	08 Sep 2021	1.76 Cash
14 May 2021	03 Mar 2021	08 Jun 2021	1.76 Cash
11 Feb 2021	16 Dec 2020	08 Mar 2021	1.76 Cash
13 Nov 2020	21 Oct 2020	08 Dec 2020	1.6 Cash
14 Aug 2020	23 Jul 2020	08 Sep 2020	1.6 Cash
15 May 2020	04 Mar 2020	08 Jun 2020	1.6 Cash
13 Feb 2020	11 Dec 2019	06 Mar 2020	1.6 Cash
14 Nov 2019	22 Oct 2019	06 Dec 2019	1.45 Cash
14 Aug 2019	02 Aug 2019	06 Sep 2019	1.45 Cash
16 May 2019	07 Mar 2019	07 Jun 2019	1.45 Cash
14 Feb 2019	07 Dec 2018	08 Mar 2019	1.45 Cash
15 Nov 2018	23 Oct 2018	07 Dec 2018	1.32 Cash
16 Aug 2018	31 Jul 2018	07 Sep 2018	1.32 Cash
16 May 2018	07 Mar 2018	08 Jun 2018	1.32 Cash
14 Feb 2018	12 Dec 2017	08 Mar 2018	1.32 Cash
16 Nov 2017	24 Oct 2017	08 Dec 2017	1.15 Cash
15 Aug 2017	28 Jul 2017	08 Sep 2017	1.15 Cash
15 May 2017	07 Mar 2017	08 Jun 2017	1.15 Cash
13 Feb 2017	20 Dec 2016	08 Mar 2017	1.15 Cash
14 Nov 2016	14 Oct 2016	08 Dec 2016	1 Cash
15 Aug 2016	22 Jul 2016	08 Sep 2016	1 Cash
13 May 2016	02 Mar 2016	08 Jun 2016	1 Cash
11 Feb 2016	15 Dec 2015	08 Mar 2016	1 Cash
12 Nov 2015	14 Oct 2015	07 Dec 2015	0.79 Cash
13 Aug 2015	28 Jul 2015	08 Sep 2015	0.79 Cash
12 May 2015	04 Mar 2015	05 Jun 2015	0.79 Cash
10 Feb 2015	17 Dec 2014	06 Mar 2015	0.79 Cash
10 Nov 2014	17 Oct 2014	05 Dec 2014	0.61 Cash
12 Aug 2014	25 Jul 2014	05 Sep 2014	0.61 Cash
13 May 2014	05 Mar 2014	06 Jun 2014	0.61 Cash
11 Feb 2014	13 Dec 2013	07 Mar 2014	0.61 Cash
12 Nov 2013	16 Oct 2013	06 Dec 2013	0.47 Cash
14 Aug 2013	26 Jul 2013	06 Sep 2013	0.47 Cash
14 May 2013	06 Mar 2013	07 Jun 2013	0.47 Cash
11 Feb 2013	13 Dec 2012	07 Mar 2013	0.47 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	4.76	2	1.54
2024	9.00	4	3.45
2023	8.52	4	2.96
2022	7.76	4	2.96
2021	7.04	4	3.13
2020	6.40	4	2.78
2019	5.80	4	2.41
2018	5.28	4	2.71
2017	4.60	4	2.65
2016	4.00	4	2.74
2015	3.16	4	1.95
2014	2.44	4	1.53
2013	1.88	4	1.65
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	12.24%
Operating Margin (TTM)	51.81%
Diluted EPS (TTM)	7.55
Quarterly Revenue Growth (YOY)	10.90%
Quarterly Earnings Growth (YOY)	-18.30%

Total Debt/Equity (MRQ)	1,035.89%
Current Ratio (MRQ)	1.26
Operating Cash Flow (TTM)	11.49 B
Levered Free Cash Flow (TTM)	13.73 B

Return on Assets (TTM)	6.40%
Return on Equity (TTM)	67.55%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)